Human Papillomavirus
Vaccines
Since 2006, two HPV vaccines have been licensed; one vaccine targets four and the other two HPV genotypes. Both vaccines are designed to protect against about 70% of cervical cancer cases worldwide (the 4-valent vaccine also protects against genital warts). The vaccines are intended for use primarily in adolescent girls aged 10–14 years. The complete series of quadrivalent vaccine is administered at day 0; 2 months; and 6 months. The bivalent vaccine is administered at day 0; 1 month; and 6 months. Repeating previous doses is not necessary if the 3-dose programme has been interrupted. Booster doses are currently not recommended. Over the next few years, HPV vaccination will be introduced into the immunization schedules of several countries.